Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Fate Therapeutics (NQ: FATE ) 3.430 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, May 29, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Fate Therapeutics < Previous 1 2 3 4 5 Next > Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday May 16, 2024 Via Benzinga FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q1 2024 May 09, 2024 FATE stock results show that Fate Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace Forecasting The Future: 8 Analyst Projections For Fate Therapeutics May 06, 2024 Via Benzinga Where Fate Therapeutics Stands With Analysts April 11, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's After-Market Session April 10, 2024 Via Benzinga Evaluating Fate Therapeutics: Insights From 5 Financial Analysts March 19, 2024 Via Benzinga Cracking The Code: Understanding Analyst Reviews For Fate Therapeutics February 27, 2024 Via Benzinga Recap: Fate Therapeutics Q4 Earnings February 26, 2024 Via Benzinga A Preview Of Fate Therapeutics's Earnings February 23, 2024 Via Benzinga Domino's To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday February 27, 2024 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga Earnings Scheduled For February 26, 2024 February 26, 2024 Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million. Via Benzinga Analyst Ratings for Fate Therapeutics November 09, 2023 Via Benzinga Billionaire Steve Cohen Is Betting Big on Fate Therapeutics (FATE) Stock January 29, 2024 Billionaire Steve Cohen is taking a massive stake in this little-known biotech company, leading FATE stock to surge more than 17%. Via InvestorPlace Pinstripes, SoFi Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session January 03, 2024 U.S. stock futures were lower this morning, with the Dow Jones futures falling around 60 points on Wednesday. Shares of Pinstripes (NYSE: PNST) shares fell in pre-market trading after surging 22% on... Via Benzinga Topics Stocks Exposures US Equities 12 Health Care Stocks Moving In Tuesday's After-Market Session December 12, 2023 Via Benzinga Recap: Fate Therapeutics Q3 Earnings November 08, 2023 Via Benzinga Analyst Ratings for Fate Therapeutics September 07, 2023 Via Benzinga The Latest Analyst Ratings for Fate Therapeutics August 16, 2023 Via Benzinga Where Fate Therapeutics Stands With Analysts May 05, 2023 Via Benzinga Fate Therapeutics: Q1 Earnings Insights May 03, 2023 Via Benzinga Fate Therapeutics Earnings Preview May 02, 2023 Via Benzinga 15 Analysts Have This to Say About Fate Therapeutics March 27, 2023 Via Benzinga Stocks That Hit 52-Week Lows On Tuesday August 01, 2023 On Tuesday, 46 stocks hit new 52-week lows. Via Benzinga Why Shares of Fate Therapeutics Soared This Week June 16, 2023 The company's shares bounced back after a stock sale last week. Via The Motley Fool $1.7M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying April 24, 2023 Although US stocks closed slightly higher on Friday, there were a few notable insider trades. Via Benzinga Expert Ratings for Fate Therapeutics March 01, 2023 Via Benzinga Analyst Ratings for Fate Therapeutics January 24, 2023 Via Benzinga Outset Medical, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session February 14, 2023 Don’t forget to check out our premarket coverage here Fate Therapeutics, Inc. (NASDAQ: FATE) fell 4.1% to $6.13 in pre-market trading. Fate Therapeutics is expected to report Q4 results on Tuesday,... Via Benzinga Sorrento Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session February 13, 2023 U.S. stock futures traded slightly higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. Via Benzinga 5 Cheapest Health Care Stocks You Should Think About January 27, 2023 The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. Via Benzinga < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.